Article
Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
Antiviral research - 1 Mar 2025
Wu Qian, Wu Hairuo, Hu Yabin, Zheng Xingyu, Chang Fangfang, Liu Yongchen, Pan Zhendong, Wang Qijie, Tang Fei, Qian Jun, Li Yuezhou, Huang Bin, Chen Keqiu, Xu Juan, Wang You, Xie Xiangping, Zhao Ping, Wu Xu, Qu Xiaowang, Li Yi-Ping
Abstract excerpt
The Omicron BA.2.86 subvariants, JN.1, KP.2, and KP.3, have become predominant globally, raising concerns about their immune evasion from vaccines and monoclonal antibody (mAb) treatments. These variants harbor more receptor-binding domain (RBD) mutations than the XBB and EG.5 sub-lineages, which are already known to compromise vaccine and therapeutic efficacy. We evaluated sera from individuals vaccinated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.